Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Hold” from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been assigned an average rating of “Hold” from the twenty-two brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $16.7895.

A number of brokerages have recently commented on ARVN. Stephens increased their price objective on Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Piper Sandler reissued an “overweight” rating and issued a $16.00 price target on shares of Arvinas in a research report on Tuesday, October 7th. Barclays upped their price objective on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Finally, BTIG Research lifted their target price on shares of Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, October 30th.

Hedge Funds Weigh In On Arvinas

Several large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its holdings in shares of Arvinas by 491.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after buying an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board grew its position in shares of Arvinas by 109.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after buying an additional 3,500 shares during the period. State of Wyoming acquired a new stake in Arvinas during the 3rd quarter worth $68,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Arvinas during the second quarter worth $74,000. Finally, Virtus Investment Advisers LLC grew its position in shares of Arvinas by 49.3% during the 2nd quarter. Virtus Investment Advisers LLC now owns 12,422 shares of the company’s stock worth $91,000 after buying an additional 4,104 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Price Performance

ARVN opened at $13.38 on Friday. The company has a market capitalization of $859.26 million, a PE ratio of -16.52 and a beta of 1.89. Arvinas has a fifty-two week low of $5.90 and a fifty-two week high of $20.38. The business has a 50-day moving average of $12.31 and a 200-day moving average of $9.85.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.27. The business had revenue of $41.90 million during the quarter, compared to analyst estimates of $29.36 million. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. Arvinas’s quarterly revenue was down 59.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.68) EPS. On average, equities research analysts expect that Arvinas will post -3.81 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.